top
Search terms
Results 1 - 2 of 2 - ordered by :
Escardio

Findings from the PARADIGM-HF trial, published simultaneously in the New England Journal of Medicine, ? are extraordinarily powerful and compelling; they are destined to change the management of ...

Date : 30/08/2014
Escardio

Over a median follow-up of 18.2 months, the primary outcome occurred in 386 of 2,373 patients (16.3%) in the dapagliflozin group and in 502 of 2,371 patients (21.2%) in the placebo group (hazard ...

Date : 01/09/2019